Biotechnology · Healthcare
Head of Investor Relations
Head of Investor Relations
Zevra Therapeutics, Inc. (ZVRA)Equibles does not estimate personal net worth.
Get an email with a short summary when Zevra Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ZVRA alertsNicole Ochsner is recorded as Head of Investor Relations at Zevra Therapeutics, Inc. (ZVRA). Nicole Ochsner has spoken on 7 earnings calls across 1 company, most recently for Zevra Therapeutics, Inc. on November 3, 2026. Zevra Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Zevra Therapeutics, Inc. includes Christal M.M. Mickle (CEO), Neil F. McFarlane (CEO and Board Member), Richard W. Pascoe (CEO and Chairman) and 7 others.
“The projections made and should be evaluated together with the risk factor section and our most recent quarterly report on Form 10-Q, our annual report on Form 10-K, and our other filings with the SEC.”
“Today, we will provide an overview of our recent accomplishments, followed by a review of our second quarter, 2026 financial results. I encourage you to read our financial results news release, which was distributed this afternoon and is available in the investor section of our website.”
“Today, we will provide an overview of our recent accomplishments, followed by a review of our first quarter 2026 financial results. I encourage you to read our financial results news release, which was distributed this afternoon and is available in the Investors section of our website.”
“Today, we will provide an overview of our recent accomplishments, followed by a review of our second quarter financial results. I encourage you to read our financial news release, which was distributed this afternoon and is available in the investor relations section of our website.”
“Today, we will provide an overview of our recent accomplishments, followed by a review of first quarter financial results. I encourage you to read our financial results news release, which was distributed this afternoon and is available in the investor section of our website.”
Biotechnology · Healthcare
Head of Investor Relations